Section one: Contracting authority
one.1) Name and addresses
Medicines Discovery Catapult
Block 35, Mereside, Alderley Park
Cheshire
SK10 4ZF
Contact
Mr Kieran McGowan
Kieran.McGowan@md.catapult.org.uk
Telephone
+44 1625708394
Country
United Kingdom
NUTS code
UKD62 - Cheshire East
Internet address(es)
Main address
Buyer's address
one.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted electronically via
one.4) Type of the contracting authority
Other type
Drug Discovery / Health
one.5) Main activity
Other activity
Drug Discovery / Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
The Supply, Delivery, Installation and Maintenance of a Floor Standing Ultracentrifuge
Reference number
DN578838
two.1.2) Main CPV code
- 38000000 - Laboratory, optical and precision equipments (excl. glasses)
two.1.3) Type of contract
Supplies
two.1.4) Short description
Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers. Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products. By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.
MDC wishes to create a new CL3 facility for innovative diagnostics, biomarkers and complex medicines and develop the UK’s onshore diagnostic capability and capacity and the associated supply chain. The project will create a national facility for testing and validation of new diagnostics, biomarkers and innovative therapeutics for disease.
The Validation Centre of Excellence will enable innovators to set up new companies with confidence, driving regional growth in high-value jobs and a sector of urgent national and global need. The Centre will build on the Lighthouse brand, creating a hub for new diagnostic and therapeutic validation.
This tender is for a Floor Standing Ultracentrifuge, which will be used in the new facility.
two.1.6) Information about lots
This contract is divided into lots: No
two.2) Description
two.2.3) Place of performance
NUTS codes
- UKD62 - Cheshire East
two.2.4) Description of the procurement
Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers. Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products. By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.
MDC wishes to create a new CL3 facility for innovative diagnostics, biomarkers and complex medicines and develop the UK’s onshore diagnostic capability and capacity and the associated supply chain. The project will create a national facility for testing and validation of new diagnostics, biomarkers and innovative therapeutics for disease.
The Validation Centre of Excellence will enable innovators to set up new companies with confidence, driving regional growth in high-value jobs and a sector of urgent national and global need. The Centre will build on the Lighthouse brand, creating a hub for new diagnostic and therapeutic validation.
This tender is for a Floor Standing Ultracentrifuge, which will be used in the new facility.
The open procedure is being followed.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60
Quality criterion - Name: Price / Weighting: 40
Price - Weighting: 40
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
End date
31 March 2022
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
four.2) Administrative information
four.2.2) Time limit for receipt of tenders or requests to participate
Date
29 November 2021
Local time
12:00pm
four.2.4) Languages in which tenders or requests to participate may be submitted
English
four.2.7) Conditions for opening of tenders
Date
29 November 2021
Local time
12:00pm
Section six. Complementary information
six.1) Information about recurrence
This is a recurrent procurement: No
six.4) Procedures for review
six.4.1) Review body
Medicines Discovery Catapult
Block 35, Mereside, Alderley Park
Cheshire
SK10 4ZF
Country
United Kingdom